APC gene guide: polyposis variants, tumor findings and family interpretation
Read an APC result carefully: tumor-suppressor biology, constitutional versus tumor findings, testing scope, uncertainty and family assessment.
Browse published, medically reviewed explanations. Search a gene, condition or research question, or narrow the collection by topic.
31 articles
Read an APC result carefully: tumor-suppressor biology, constitutional versus tumor findings, testing scope, uncertainty and family assessment.
Understand PTPN11 and SHP-2, disease mechanisms, constitutional versus tumor findings and evidence-based RASopathy variant review.
Understand Lynch syndrome, tumor versus inherited testing, uncertain results and family screening, with clear questions for a genetics consultation.
Read gene-therapy trial results step by step: outcomes, controls, absolute benefit, safety, small subgroups and long-term follow-up.
Ataxia-telangiectasia affects movement, immunity and cancer risk. Understanding whether one or both ATM gene copies are affected is essential to interpreting a genetic result.
DICER1 links RNA processing to a distinctive tumor spectrum. For researchers, meaningful risk estimates depend on age, recruitment and whether an outcome includes benign growths.
Understand DPYD and DPD testing before fluorouracil or capecitabine: genotype, phenotype, negative results and practical questions for the oncology team.
Read ACMG/AMP variant classifications with practical examples, Bayesian odds and points, gene-specific guidance, and safeguards against double-counting evidence.
Read a KRAS G12C result: exact variant, tumour versus plasma testing, treatment context and trial outcomes, with practical examples.
Testing relatives for a known pathogenic variant can clarify inherited risk. The original report, family context and follow-up plan determine how useful the result becomes.
Learn why a negative genetic test may leave questions open, with practical examples of test scope, mosaicism, repeat expansions and reanalysis.
An NCI research agenda highlights living-cell drug testing alongside genomics. A pediatric feasibility study shows why useful laboratory results still require stronger clinical evidence.